Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Joseph-Ridge

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Rheumatic Diseases Clinics of North America|May 24, 2006
Clinical trials in crystal arthropathyNancy Joseph-Ridge, Susan Cazzetta, Patricia MacDonald
Journal of Clinical Pharmacology|July 21, 2006
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDsReza Khosravan, Jing-Tao Wu, Nancy Joseph-Ridge, et al.
The Journal of Rheumatology|August 4, 2004
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care populationKatrine L Wallace, Aylin A Riedel, Nancy Joseph-Ridge, et al.
British Journal of Clinical Pharmacology|October 24, 2007
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsReza Khosravan, Brian Grabowski, Jing-Tao Wu, et al.
Clinical Pharmacokinetics|August 4, 2006
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjectsReza Khosravan, Brian A Grabowski, Jing-Tao Wu, et al.
Journal of Clinical Pharmacology|July 19, 2008
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseReza Khosravan, Michael J Kukulka, Jing-Tao Wu, et al.
The Journal of Rheumatology|August 4, 2004
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claimsAylin A Riedel, Michael Nelson, Nancy Joseph-Ridge, et al.
Nucleosides, Nucleotides & Nucleic Acids|July 5, 2008
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapyMichael A Becker, Patricia A MacDonald, Barbara J Hunt, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 18, 2006
Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care settingAylin Altan Riedel, Mike Nelson, Katrine Wallace, et al.
American Journal of Therapeutics|January 22, 2005
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentMichael D Mayer, Reza Khosravan, Laurent Vernillet, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Rheumatic Diseases Clinics of North America|May 24, 2006
Clinical trials in crystal arthropathyNancy Joseph-Ridge, Susan Cazzetta, Patricia MacDonald
Journal of Clinical Pharmacology|July 21, 2006
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDsReza Khosravan, Jing-Tao Wu, Nancy Joseph-Ridge, et al.
The Journal of Rheumatology|August 4, 2004
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care populationKatrine L Wallace, Aylin A Riedel, Nancy Joseph-Ridge, et al.
British Journal of Clinical Pharmacology|October 24, 2007
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsReza Khosravan, Brian Grabowski, Jing-Tao Wu, et al.
Clinical Pharmacokinetics|August 4, 2006
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjectsReza Khosravan, Brian A Grabowski, Jing-Tao Wu, et al.
Journal of Clinical Pharmacology|July 19, 2008
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseReza Khosravan, Michael J Kukulka, Jing-Tao Wu, et al.
The Journal of Rheumatology|August 4, 2004
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claimsAylin A Riedel, Michael Nelson, Nancy Joseph-Ridge, et al.
Nucleosides, Nucleotides & Nucleic Acids|July 5, 2008
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapyMichael A Becker, Patricia A MacDonald, Barbara J Hunt, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 18, 2006
Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care settingAylin Altan Riedel, Mike Nelson, Katrine Wallace, et al.
American Journal of Therapeutics|January 22, 2005
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentMichael D Mayer, Reza Khosravan, Laurent Vernillet, et al.
Pageof 3